Gossamer Bio, Inc. (GOSS) Deep Dive Video

Summary

A single inhaled, disease-modifying PAH bet with a February 2026 binary catalyst—de-risked by Chiesi economics but still exposed to trial failure, competitive benchmarks, and future dilution.

View GOSS stock page · Read the GOSS research report

Loading the video player…